REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo and Merck , known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3 trial evaluating the...

Related Keywords

Canada ,Japan ,Colombo ,Western ,Sri Lanka ,United States ,America ,Daiichi Sankyo ,Raludotatug Deruxtecan ,Mark Rutstein ,European Society For Medical Oncology Congress ,Linkedin ,Facebook ,Merck Research Laboratories ,Sarah Cannon Research Institute ,Exchange Commission ,Twitter ,Society For Gynecologic Oncology ,Statement Of Merck Co Inc ,Oncology Clinical Development ,Youtube ,Global Clinical Development ,Astrazeneca ,Instagram ,Development Innovations In Nashville ,Merck Co Inc ,European Society ,Medical Oncology Congress ,Gynecologic Oncology ,Global Head ,Marjorie Green ,Senior Vice President ,Late Stage Oncology ,Merck Research ,North America ,Merck Collaboration ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Population Fact ,Stat Facts ,